Aktie A2JP49 NEON THERAPEUTICS, INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren
Inaktiver Wert

Andere Sprachen Neon Therapeutics, Inc.

Aktien

A2JP49

US64050Y1001

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
NEON THERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K)
Neon Therapeutics, Inc. Announces Management Changes
Neon Therapeutics, Inc.(NasdaqGS:NTGN) dropped from S&P TMI Index
BioNTech SE completed the acquisition of Neon Therapeutics, Inc. from Third Rock Ventures, LLC and others.
NEON THERAPEUTICS, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)
Neon Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2020
Neon Therapeutics, Inc. Announces Acceptance of European Clinical Trial Authorization Application for NEO-PTC-01
Neon Therapeutics Announces Acceptance of European Clinical Trial Authorization Application for NEO-PTC-01
Infinity Pharmaceuticals : Augments Board of Directors with Appointment of Richard Gaynor, M.D
NEON THERAPEUTICS : Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K)
NEON THERAPEUTICS, INC. : Results of Operations and Financial Condition (form 8-K)
Neon Therapeutics : Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update
Neon Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2019
NEON THERAPEUTICS INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Neon Therapeutics, Inc. - NTGN
NEON THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits (form 8-K)
BioNTech SE entered into an Agreement to acquire Neon Therapeutics, Inc. from Third Rock Ventures, LLC and others for $73.6 million.
Neon Therapeutics : Submits European Clinical Trial Authorization Application for Personal Neoantigen-Targeted T Cell Therapy NEO-PTC-01
Neon Therapeutics, Inc. Submits European Clinical Trial Authorization Application for Personal Neoantigen-Targeted T Cell Therapy NEO-PTC-01
NEON THERAPEUTICS, INC. : Costs Associated with Exit or Disposal Activities (form 8-K)
Neon Therapeutics Announces New Strategic Focus on Novel T Cell Programs
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A2JP49 Aktie
  4. Nachrichten Neon Therapeutics, Inc.
  5. Andere Sprachen